Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428–44.

Article  CAS  PubMed  Google Scholar 

Su J, Liang Y, He X. Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2019. Front Med (Lausanne). 2024;11:1384314.

Article  PubMed  PubMed Central  Google Scholar 

Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694–704.

Article  CAS  PubMed  Google Scholar 

Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853–65.

Article  PubMed  Google Scholar 

Yoo C, Saborowski A, Hyung J, Wenzel P, Kim I, Wege H, et al. Liposomal irinotecan for previously treated patients with biliary tract cancer: a pooled analysis of NIFTY and NALIRICC trials. J Hepatol. 2025;83:909–16.

Article  CAS  PubMed  Google Scholar 

Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690–701.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tureci O, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011;481:83–92.

Article  CAS  PubMed  Google Scholar 

Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC, et al. Claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. 2001;21:7380–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624–34.

Article  CAS  PubMed  Google Scholar 

Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655–68.

Article  CAS  PubMed  Google Scholar 

Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, La Sorda R, et al. The Trop-2 signalling network in cancer growth. Oncogene. 2013;32:1594–600.

Article  CAS  PubMed  Google Scholar 

Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci USA. 2020;117:2032–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Svec J, Stastna M, Janeckova L, Hrckulak D, Vojtechova M, Onhajzer J, et al. TROP2 represents a negative prognostic factor in colorectal adenocarcinoma and its expression is associated with features of epithelial-mesenchymal transition and invasiveness. Cancers (Basel). 2022;14:4137.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222–33.

Article  CAS  PubMed  Google Scholar 

Dum D, Taherpour N, Menz A, Hoflmayer D, Volkel C, Hinsch A, et al. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology. 2022;89:245–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41.

Article  CAS  PubMed  Google Scholar 

Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32:1148–56.

Article  CAS  PubMed  Google Scholar 

Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol. 2024;42:2860–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Flechon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39:2474–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, et al. Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med. 2024;30:3709–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bychkov A, Sampatanukul P, Shuangshoti S, Keelawat S. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma. Pathology. 2016;48:425–33.

Article  CAS  PubMed  Google Scholar 

Angerilli V, Sacchi D, Rizzato M, Gasparello J, Ceccon C, Sabbadin M, et al. Claudin 18.2: a promising actionable target in biliary tract cancers. ESMO Open. 2025;10:105049.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kinzler MN, Gretser S, Schulze F, Bankov K, Abedin N, Bechstein WO, et al. Expression of claudin-18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre. Histopathology. 2025;86:640–6.

Article  PubMed  Google Scholar 

Iwaya M, Hayashi H, Nakajima T, Matsuda K, Kinugawa Y, Tobe Y, et al. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy. Histopathology. 2021;79:227–37.

Article  PubMed  Google Scholar 

Ruan DY, Liu FR, Wei XL, Luo SX, Zhuang ZX, Wang ZN, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26:227–38.

Article  CAS  PubMed  Google Scholar 

Raufi AG, Goyal L, Smyth E, Szekeres P, Petrone M, Hobson R, et al. CLARITY-PanTumor01: a phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors. J Clin Oncol. 2024;42:TPS3163.

Article  Google Scholar 

Qiu S, Zhang J, Wang Z, Lan H, Hou J, Zhang N, et al. Targeting Trop-2 in cancer: recent research progress and clinical application. Biochimica et Biophysica Acta (BBA). 2023;1878:188902.

CAS  Google Scholar 

University of Kansas Medical Center. Sacituzumab govitecan for the treatment for patients with locally advanced, recurrent, or metastatic cholangiocarcinoma. US National Library of Medicine. 2024. https://clinicaltrials.gov/study/NCT06178588. Accessed 27 June 2025.

AstraZeneca. Study of Dato‑DxD as monotherapy and in combination with anti‑cancer agents in patients with advanced solid tumours (TROPION‑PanTumor03). US National Library of Medicine. 2022.